Total raised
$24.2M
Last: PIPE 2025-09
Stage
Public
Founded
2017
Headcount
32
HQ
Herzliya
Sector
Health Tech & Life Sciences
About
NeuroSense Therapeutics is a drug development company offering a treatment for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The companys drug, PrimeC, is a unique formulation combining two FDA-approved compounds for unrelated conditions. The company was granted an orphan drug designation by the FDA and the EMA for the use of PrimeC in ALS patients. NeuroSense Therapeutics is currently running two clinical trials in patients with ALS, in Israel and the United States.
Funding history · 5 rounds · $24.2M total
2025-09
PIPE
$500K
2024-12
PIPE
$5.0M
2020-04
Equity crowdfunding
$120K
2020-02
Equity crowdfunding
$580K
2019-08
Equity crowdfunding
$1.5M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is NeuroSense Therapeutics' primary focus?
- NeuroSense Therapeutics is a drug development company focused on creating treatments for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their lead drug candidate is PrimeC.
- When did NeuroSense Therapeutics go public on NASDAQ?
- NeuroSense Therapeutics went public on NASDAQ in December 2021, and again in June 2023, under the ticker NRSN.
- Has NeuroSense Therapeutics' drug PrimeC received any special designations?
- Yes, PrimeC was granted an orphan drug designation by both the FDA and the EMA for its use in ALS patients.
- What was the total amount raised by NeuroSense Therapeutics through funding rounds?
- NeuroSense Therapeutics has raised a total of $24.2 million USD through various funding rounds, including equity crowdfunding and PIPE investments. For a full financing history, please refer to startupim.
- What was a significant finding from the PARADIGM Phase 2b trial of PrimeC in ALS?
- In March 2026, JAMA Neurology published results from the PARADIGM Phase 2b trial of PrimeC in ALS, demonstrating meaningful clinical outcomes and biological activity. Earlier, in February 2026, NeuroSense announced a statistically significant 65% reduction in the risk of death and a greater than 14-month median survival benefit with PrimeC in ALS.
- What regulatory milestone did NeuroSense Therapeutics achieve in November 2025 regarding PrimeC?
- In November 2025, NeuroSense Therapeutics received FDA clearance to initiate a pivotal Phase 3 trial for PrimeC in ALS.
- What patent was granted to NeuroSense Therapeutics in January 2026?
- In January 2026, NeuroSense Therapeutics was granted a U.S. patent for the treatment of Alzheimer's Disease.
- What was the outcome of NeuroSense Therapeutics' Alzheimer's Phase 2 study in December 2025?
- In December 2025, NeuroSense Therapeutics confirmed the favorable safety and tolerability of PrimeC in an Alzheimer's Phase 2 study.
- What was the latest funding event for NeuroSense Therapeutics?
- In September 2025, NeuroSense Therapeutics announced a $500,000 PIPE financing round.
- What was NeuroSense Therapeutics' status regarding NASDAQ compliance in January 2025?
- In January 2025, NeuroSense Therapeutics regained compliance with Nasdaq's minimum equity requirement.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsamyotrophic-lateral-sclerosis-alsdrug-discoverypharma-companiesneurosciencebiotechnologydegenerative-diseasesrare-diseases